Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Атезолизумаб в комбинации с химиотерапией в неоадъювантном режиме увеличил частоту полных патоморфологических ответов у пациенток с ранним тройным негативным раком молочной железы вне зависимости от статуса PD-L1
Атезолизумаб в комбинации с химиотерапией в неоадъювантном режиме увеличил частоту полных патоморфологических ответов у пациенток с ранним тройным негативным раком молочной железы вне зависимости от статуса PD-L1
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. LBA11, Harbeck N et al. ESMO 2020. Ann Oncol 2020; 31 (Suppl_4): S1142–S1215.
2. Mittendorf EA, Zhang H, Barrios CH, et al. Lancet. 2020 и 396(10257):1090-1100.
3. Инструкция по медицинскому применению препарата Тецентрик®, РУ №ЛП-004652 от 17.08.2020.
[Instruktsiia po meditsinskomu primeneniiu preparata Tetsentrik®, RU №LP-004652 ot 17.08.2020 (in Russian).]
4. Эл. ресурс: https://www.fda.gov/media/83507/download, Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry.
[Available from: https://www.fda.gov/media/83507/download, Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry (in Russian).]
5. 2020. Эл. ресурс: https://www.roche.com/media/releases/med-cor-2020-09-19.htm
[2020. Available from: https://www.roche.com/media/releases/med-cor-2020-09-19.htm (in Russian).]
6. LBA16, Emens LA et al. ESMO 2020. Ann Oncol 2020; 31 (Suppl_4): S1142–S1215.
7. Эл. ресурс:
https://clinicaltrials.gov/ct2/resultscond=&term=atezolizumab&cntry=&state=&city=&dist=
[Available from:
https://clinicaltrials.gov/ct2/resultscond=&term=atezolizumab&cntry=&state=&city=&dist= (in Russian).]
8. Эл. ресурс: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. World Health Organization: Globocan 2018 – Breast Cancer Factsheet.
[Available from: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. World Health Organization: Globocan 2018 – Breast Cancer Factsheet (in Russian).]
9. Yao H et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017; 8 (1): 1913–24.
10. Эл. ресурс: https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what, BreastCancer.org. What is Triple-Negative Breast Cancer?
[Available from: https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what, BreastCancer.org. What is Triple-Negative Breast Cancer? (in Russian).]
11. Cancer Treatment Centers of America. Triple negative breast cancer risk factors. https://www.cancercenter.com/breast-cancer/risk-factors/tab/triple-negative-breast-cancer-risk-facto...
12. Pal SK et al. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125 (3): 627–36.
13. 2020, Tecenrtiq® (atezolizumab) FDA approval. https://www.accessdata.fda.gov/
drugsatfda_docs/label/2019/761034s018lbl.pdf
14. Tecenrtiq® (atezolizumab) SmPc. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf
2. Mittendorf EA, Zhang H, Barrios CH, et al. Lancet. 2020 и 396(10257):1090-1100.
3. Instruktsiia po meditsinskomu primeneniiu preparata Tetsentrik®, RU №LP-004652 ot 17.08.2020 (in Russian).
4. Available from: https://www.fda.gov/media/83507/download, Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry (in Russian).
5. 2020. Available from: https://www.roche.com/media/releases/med-cor-2020-09-19.htm (in Russian).
6. LBA16, Emens LA et al. ESMO 2020. Ann Oncol 2020; 31 (Suppl_4): S1142–S1215.
7. Available from:
https://clinicaltrials.gov/ct2/resultscond=&term=atezolizumab&cntry=&state=&city=&dist= (in Russian).
8. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. World Health Organization: Globocan 2018 – Breast Cancer Factsheet (in Russian).
9. Yao H et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017; 8 (1): 1913–24.
10. Available from: https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what, BreastCancer.org. What is Triple-Negative Breast Cancer? (in Russian).
11. Cancer Treatment Centers of America. Triple negative breast cancer risk factors. https://www.cancercenter.com/breast-cancer/risk-factors/tab/triple-negative-breast-cancer-risk-facto...
12. Pal SK et al. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125 (3): 627–36.
13. 2020, Tecenrtiq® (atezolizumab) FDA approval. https://www.accessdata.fda.gov/
drugsatfda_docs/label/2019/761034s018lbl.pdf
14. Tecenrtiq® (atezolizumab) SmPc. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf
2. Mittendorf EA, Zhang H, Barrios CH, et al. Lancet. 2020 и 396(10257):1090-1100.
3. Инструкция по медицинскому применению препарата Тецентрик®, РУ №ЛП-004652 от 17.08.2020.
[Instruktsiia po meditsinskomu primeneniiu preparata Tetsentrik®, RU №LP-004652 ot 17.08.2020 (in Russian).]
4. Эл. ресурс: https://www.fda.gov/media/83507/download, Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry.
[Available from: https://www.fda.gov/media/83507/download, Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry (in Russian).]
5. 2020. Эл. ресурс: https://www.roche.com/media/releases/med-cor-2020-09-19.htm
[2020. Available from: https://www.roche.com/media/releases/med-cor-2020-09-19.htm (in Russian).]
6. LBA16, Emens LA et al. ESMO 2020. Ann Oncol 2020; 31 (Suppl_4): S1142–S1215.
7. Эл. ресурс:
https://clinicaltrials.gov/ct2/resultscond=&term=atezolizumab&cntry=&state=&city=&dist=
[Available from:
https://clinicaltrials.gov/ct2/resultscond=&term=atezolizumab&cntry=&state=&city=&dist= (in Russian).]
8. Эл. ресурс: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. World Health Organization: Globocan 2018 – Breast Cancer Factsheet.
[Available from: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. World Health Organization: Globocan 2018 – Breast Cancer Factsheet (in Russian).]
9. Yao H et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017; 8 (1): 1913–24.
10. Эл. ресурс: https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what, BreastCancer.org. What is Triple-Negative Breast Cancer?
[Available from: https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what, BreastCancer.org. What is Triple-Negative Breast Cancer? (in Russian).]
11. Cancer Treatment Centers of America. Triple negative breast cancer risk factors. https://www.cancercenter.com/breast-cancer/risk-factors/tab/triple-negative-breast-cancer-risk-facto...
12. Pal SK et al. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125 (3): 627–36.
13. 2020, Tecenrtiq® (atezolizumab) FDA approval. https://www.accessdata.fda.gov/
drugsatfda_docs/label/2019/761034s018lbl.pdf
14. Tecenrtiq® (atezolizumab) SmPc. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf
________________________________________________
2. Mittendorf EA, Zhang H, Barrios CH, et al. Lancet. 2020 и 396(10257):1090-1100.
3. Instruktsiia po meditsinskomu primeneniiu preparata Tetsentrik®, RU №LP-004652 ot 17.08.2020 (in Russian).
4. Available from: https://www.fda.gov/media/83507/download, Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry (in Russian).
5. 2020. Available from: https://www.roche.com/media/releases/med-cor-2020-09-19.htm (in Russian).
6. LBA16, Emens LA et al. ESMO 2020. Ann Oncol 2020; 31 (Suppl_4): S1142–S1215.
7. Available from:
https://clinicaltrials.gov/ct2/resultscond=&term=atezolizumab&cntry=&state=&city=&dist= (in Russian).
8. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. World Health Organization: Globocan 2018 – Breast Cancer Factsheet (in Russian).
9. Yao H et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017; 8 (1): 1913–24.
10. Available from: https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what, BreastCancer.org. What is Triple-Negative Breast Cancer? (in Russian).
11. Cancer Treatment Centers of America. Triple negative breast cancer risk factors. https://www.cancercenter.com/breast-cancer/risk-factors/tab/triple-negative-breast-cancer-risk-facto...
12. Pal SK et al. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125 (3): 627–36.
13. 2020, Tecenrtiq® (atezolizumab) FDA approval. https://www.accessdata.fda.gov/
drugsatfda_docs/label/2019/761034s018lbl.pdf
14. Tecenrtiq® (atezolizumab) SmPc. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.